Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

Published:2023-01 Issue:1 Volume:10 Page:e14-e23
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Herrera Alex F,Chen Lu,Nieto Yago,Holmberg Leona,Johnston Patrick,Mei Matthew,Popplewell Leslie,Armenian Saro,Cao Thai,Farol Leonardo,Sahebi Firoozeh,Spielberger Ricardo,Chen Robert,Nademanee Auayporn,Puverel Sandrine,Nwangwu Mary,Lee Peter,Song Joo,Skarbnik Alan,Kennedy Neena,Peters Lacolle,Rosen Steven T,Kwak Larry W,Forman Stephen J,Feldman Tatyana

Funder

Bristol-Myers Squibb

National Institutes of Health

Leukemia & Lymphoma Society

National Cancer Institute

Lymphoma Research Foundation of America

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

2. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse;Moskowitz;Blood,2018

3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial;Moskowitz;Lancet,2015

4. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study;Moskowitz;Lancet Oncol,2015

5. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma;Herrera;Ann Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes;HemaSphere;2024-09

2. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease;American Society of Clinical Oncology Educational Book;2024-06

3. The Pediatric Approach to Hodgkin Lymphoma;Seminars in Hematology;2024-05

4. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy – A case report and literature review;Acta Paediatrica;2024-04-10

5. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations;Translational Oncology;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3